NSE மற்றும் BSE-யின் ஒவ்வொரு கார்ப்பரேட் அறிவிப்பும், AI-யால் சில நிமிடங்களில் படிக்கப்பட்டு விளக்கப்படுகிறது — தாக்கம், முக்கிய புள்ளிவிவரங்கள், குறுகிய/நீண்டகாலப் பார்வை, கவனிக்க வேண்டியவை.
குறிப்பு: இவை NSE பொது அறிக்கைகளின் AI-உருவாக்கிய, கல்வி நோக்கச் சுருக்கங்கள் — ஒவ்வொரு ஆவணத்தையும் ஆதாரமாகக் கொண்டவை, ஆனால் முதலீட்டு ஆலோசனை அல்ல, மேலும் முழுமையற்றதாகவும் இருக்கலாம். அசல் அறிக்கையுடன் சரிபார்க்கவும், செயல்படுவதற்கு முன் SEBI-பதிவு பெற்ற முதலீட்டு ஆலோசகரை அணுகவும்.
GKSL Reports Zero Deviation in Utilization of ₹250.80 Crore IPO Proceeds
Gujarat Kidney And Super Speciality Limited (GKSL) has submitted its statement of deviation for the quarter ended December 31, 2025, confirming that the ₹250.80 crore raised via equity issuance is being handled as per the original objects. The funds were raised on December 24, 2025, and as of the quarter-end, no deviations or variations in utilization were reported. Major allocations include ₹77 crore for the acquisition of Parekhs Hospital and ₹30.10 crore for a new women's hospital in Vadodara. Brickwork Ratings India Private Limited is acting as the monitoring agency for these funds.
முக்கிய அம்சங்கள்
Raised a total of ₹250.80 crore through an equity share issue on December 24, 2025.Reported zero deviation or variation in the use of proceeds for the third quarter of FY26.Allocated ₹77 crore for the acquisition of Parekhs Hospital Private Limited at Ahmedabad.Earmarked ₹30.10 crore for capital expenditure for a new women's healthcare hospital in Vadodara.Allocated ₹87.44 crore for inorganic growth through unidentified acquisitions and general corporate purposes.
👀 கவனிக்க வேண்டியவை
Investors should track subsequent quarterly reports to ensure the timely and efficient deployment of funds into the stated acquisition and expansion projects. The successful execution of these capital-intensive projects will be a key driver for the company's long-term growth.
GKSL Receives NCLT Approval for Voluntary Revision of Financials and Board Reports (FY22-FY24)
Gujarat Kidney and Super Speciality Limited (GKSL) has received NCLT approval to voluntarily revise its Board Reports and Financial Statements for three financial years (FY22, FY23, and FY24). The revisions primarily address clerical errors, such as incorrect board meeting dates and director appointment timelines. Crucially, the company is correcting a miscategorization in FY24 where a business transfer amount was wrongly labeled as a 'Loan to directors.' Management has confirmed that these revisions have no impact on the company's financial performance, operations, or other activities.
முக்கிய அம்சங்கள்
NCLT Ahmedabad approved the voluntary revision of Board Reports and Financial Statements for FY 2021-22, 2022-23, and 2023-24.Correction of a miscategorized 'Loan to directors' in FY24 notes, which was actually related to a Business Transfer Agreement.Rectification of clerical errors regarding the company's conversion date from Private to Public (corrected to 24/11/2023).The company is directed to pay a nominal fee of ₹10,000 and file revised Form AOC-4 within 30 days.Management and auditors state there is no quantifiable monetary impact on the company's financial or operational status.
👀 கவனிக்க வேண்டியவை
Investors should view this as a corrective governance measure to ensure regulatory accuracy; no immediate action is required as the financials remain fundamentally unchanged. Monitor the filing of the revised reports to confirm the 'Loan to directors' miscategorization is officially resolved.
GKSL Q3 FY26 Standalone PAT Grows 5.4% YoY to ₹2.33 Cr; Revenue Up 14.8%
Gujarat Kidney And Super Speciality Limited (GKSL) reported a steady performance for the quarter ended December 31, 2025, with standalone revenue from operations rising 14.8% YoY to ₹976.45 Lacs. Net profit for the quarter saw a modest increase to ₹233.26 Lacs from ₹221.20 Lacs in the previous year. For the nine-month period, the company achieved a PAT of ₹853.36 Lacs, representing an 8.8% growth compared to the same period last year. However, bottom-line growth was slightly constrained by a significant jump in finance costs and other operating expenses.
முக்கிய அம்சங்கள்
Standalone Revenue from Operations increased to ₹976.45 Lacs in Q3 FY26 from ₹850.64 Lacs in Q3 FY25.Standalone Profit After Tax (PAT) for the quarter stood at ₹233.26 Lacs, up 5.4% year-on-year.Nine-month (9M FY26) Standalone PAT reached ₹853.36 Lacs compared to ₹784.42 Lacs in 9M FY25.Finance costs for the quarter rose sharply to ₹29.22 Lacs from ₹10.68 Lacs in the corresponding quarter last year.The Board approved consolidated results including subsidiaries Raj Palmland Hospital and Harmony Medicare.
👀 கவனிக்க வேண்டியவை
Investors should note the steady revenue growth in the healthcare segment but remain cautious about rising finance costs which may impact margins. The stock's performance will likely depend on the successful integration and contribution of its newly consolidated hospital subsidiaries.
GKSL to Acquire 51% Stake in Patel Pharmacy and Patel Multispeciality Hospital for ₹12.50 Crore
Gujarat Kidney And Super Speciality Limited (GKSL) has approved the acquisition of a 51% controlling stake in two entities: Patel Pharmacy and Patel Multispeciality Hospital and ICU. The total cash consideration for these acquisitions is approximately ₹12.50 crore, with ₹3.70 crore allocated for the pharmacy and ₹8.80 crore for the hospital. Both target entities are based in Ankleshwar, Gujarat, and have been operational since 2015. This strategic move is aimed at consolidating GKSL's position in the healthcare sector and diversifying its service portfolio beyond specialized kidney care.
முக்கிய அம்சங்கள்
Acquisition of 51% stake in Patel Pharmacy for ₹3.70 crore (FY25 turnover: ₹2.57 crore)Acquisition of 51% stake in Patel Multispeciality Hospital and ICU for ₹8.80 crore (FY25 turnover: ₹6.46 crore)Total investment of ₹12.50 crore to be completed via cash consideration within approximately 2 monthsStrategic expansion into multispeciality healthcare and pharmacy services to diversify business portfolioTarget entities are established firms in Ankleshwar, Gujarat, with a track record dating back to 2015
👀 கவனிக்க வேண்டியவை
Investors should view this as a growth-oriented move that diversifies the company's revenue streams. Monitor the integration of these assets and their contribution to consolidated margins in the next few quarters.
GKSL to Acquire 49% Stake in Harmony Medicare for ₹10.78 Cr and Ashwini Medical for ₹14 Cr
Gujarat Kidney And Super Speciality Limited (GKSL) is consolidating its healthcare portfolio by acquiring the remaining 49% of Harmony Medicare for ₹10.78 Crores, bringing its ownership to 100%. The company is also completing the acquisition of Ashwini Medical Centre for a total of ₹14 Crores, utilizing ₹12.40 Crores from its IPO proceeds for the final payment. Harmony Medicare has shown strong revenue growth, reaching ₹42.29 Crores in FY25 compared to ₹27.70 Crores in FY23. These moves are expected to be finalized within two months and aim to strengthen GKSL's market position in Gujarat.
முக்கிய அம்சங்கள்
Acquisition of 49% stake in Harmony Medicare for ₹10.78 Crores to achieve 100% ownershipHarmony Medicare's revenue increased by 52.6% over two years, reaching ₹42.29 Crores in FY25Approval of ₹12.40 Crores payment from IPO funds for the ₹14 Crores acquisition of Ashwini Medical CentreAshwini Medical Centre, a partnership firm, reported a turnover of ₹4.51 Crores for FY25Both acquisitions are targeted for completion within a two-month timeframe
👀 கவனிக்க வேண்டியவை
Investors should view these acquisitions as a positive step toward scale and consolidation of high-growth subsidiaries. Monitor the integration of these entities and their impact on consolidated margins in the upcoming quarterly results.
📊 கடந்த 7 நாட்கள் — உணர்வு அடிப்படையில் பகுப்பாய்வு செய்யப்பட்ட அறிவிப்புகள்
GKSL to Acquire 100% Stake in Parekhs Hospital for Rs 77 Crore
Gujarat Kidney And Super Speciality Limited (GKSL) has announced the 100% acquisition of Parekhs Hospital Private Limited for a cash consideration of Rs 77 crore. Parekhs Hospital is an Ahmedabad-based healthcare provider with a steady turnover, reporting Rs 25.67 crore in FY 2024-25. The acquisition is intended to strengthen GKSL's presence in the healthcare sector and diversify its business portfolio. The transaction is expected to be completed within approximately two months, making Parekhs Hospital a wholly-owned subsidiary.
முக்கிய அம்சங்கள்
Acquisition of 100% equity stake (2,55,000 shares) in Parekhs Hospital Private Limited for Rs 77 crore.Target company reported consistent annual turnover: Rs 25.67 Cr (FY25), Rs 26.36 Cr (FY24), and Rs 24.08 Cr (FY23).The deal is a pure cash consideration and is expected to close within 2 months.Parekhs Hospital has been operational since 2006 and is located in Ahmedabad, Gujarat.
👀 கவனிக்க வேண்டியவை
Investors should view this as a significant inorganic growth move, though they should monitor how GKSL funds the Rs 77 crore acquisition and its impact on future debt-to-equity levels.
⚠️இந்தத் தளம் எவ்வாறு உருவாக்கப்படுகிறது: சந்தைத் தரவுப் பக்கங்கள் NSE/BSE வெளியீடுகள் மற்றும் நிறுவனங்களின் தாக்கல்களிலிருந்து தானாகக் கணக்கிடப்படுகின்றன; செய்திக் கட்டுரைகளும் அறிவிப்புப் பகுப்பாய்வுகளும் AI உதவியுடன் எழுதப்படுகின்றன, மனித மேற்பார்வையுடன்: AI உருவாக்குவதை எங்கள் ஆசிரியர்கள் மதிப்பாய்வு செய்கின்றனர். இரண்டிலும் பிழைகள் இருக்கலாம். எந்தவொரு முதலீட்டு முடிவுக்கு முன்பும் அசல் மூலங்களில் சரிபார்க்கவும். முதலீட்டு ஆலோசனை அல்ல; Flash Finance SEBI-பதிவு பெற்றது அல்ல. நாங்கள் AI-ஐ எவ்வாறு பயன்படுத்துகிறோம்
🎁 ஆரம்பகால ஆதரவாளர்களுக்கு மட்டும் · குறுகிய கால சலுகை
எங்கள் AI பங்குச் சந்தை பகுப்பாய்வு: டெலிகிராம், வாட்ஸ்அப்பில் இலவசம்
⚡ 3500+ நிறுவனங்களை நாங்கள் உடனுக்குடன் கண்காணிக்கிறோம். NSE-யில் ஒரு நிறுவன அறிவிப்பு வெளியானதுமே, எங்கள் AI அதைப் படித்து, சுருக்கி, அதன் தாக்கத்தைச் சில நொடிகளில் உங்களுக்குச் சொல்கிறது.
இதுபோன்ற AI பகுப்பாய்வுக்குக் கட்டணத் தளங்கள் ஆண்டுக்கு ₹1,00,000-க்கும் மேல் வசூலிக்கின்றன. எங்கள் சேனல்களில் இது இலவசம்.
